Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Baricitinib benefits even AD patients with comorbidities

Pearl Toh
08 May 2020

Treatment with baricitinib led to clinically meaningful improvements in itch and skin symptoms in patients with moderate-to-severe atopic dermatitis (AD), even in those with additional comorbid atopic conditions, according to a pooled analysis of two phase III studies released in the AAAAI 2020 Meeting.

“Asthma and allergic rhinitis are frequent atopic comorbidities in AD and may influence the management of patients with AD,” said the researchers.

“[In the current pooled analysis of studies on baricitinib,] there were no treatment-effect differences between groups of patients with or without comorbidity,” they added.

Baricitinib is a selective and reversible oral inhibitor of Janus kinase (JAK) 1 and JAK2, which has previously been approved for treatment of rheumatoid arthritis. 

The current analysis pooled data from two phase III, double-blind trials of baricitinib in patients with moderate-to-severe AD: BREEZE-AD1 (n=624) and BREEZE-AD2 (n=615). Patients were randomized in a 2:1:1:1 ratio to receive placebo or baricitinib 1 mg, 2 mg, or 4 mg once daily for 16 weeks. [AAAAI 2020, abstract 610]

As high as 71 percent (n=878) of the patients had at least one atopic comorbidity, with allergic rhinitis being the most common (57.7 percent), followed by seasonal allergy (45.9 percent), asthma (41.2 percent), and food allergy (40.7 percent).

Among patients with atopic comorbidities, there were significantly more patients who attained an IGA* response (IGA≤2; disease rated as mild or less) in all the baricitinib groups compared with placebo at week 16 (29.8 percent, 25.0 percent, and 18.6 percent vs 9.8 percent for 4-, 2-, and 1-mg baricitinib vs placebo, respectively; p≤0.01 for all).

Similar improvements were seen in the proportion of patients achieving 50 percent reduction in EASI** score (EASI50), in favour of baricitinib over placebo (32.7 percent, 29.0 percent, and 20.3 percent, vs 11.5 percent; p≤0.01 for all).

Improvements in itch symptoms were also greater with baricitinib than placebo among the patients with atopic comorbidities, as indicated by ≥4 points improvement on the Itch Numeric Rating Scale (21.6 percent, 16.6 percent, and 10.1 percent vs 4.4 percent; p≤0.05 for all).

In addition, baritinib consistently improved sleep disturbance due to itch at week 16 among the patients with comorbid atopic conditions. According to the researchers, moderate-to-severe AD is characterized by severe itching, which can lead to damaged skin and sleep loss.

When comparing the treatment effects in patients with atopic comorbidities vs those without, the benefits of baricitinib were consistent for all outcomes mentioned above.

“Overall safety outcomes for patients with atopic comorbidities were similar to outcomes in the overall trial population,” the researchers reported.  

Recently released data from the BREEZE-AD5 trial showed that the 2-mg dose of baricitinib monotherapy met its primary endpoint of ≥75 percent improvement in EASI at week 16 compared with placebo.

According to the principal investigator, the results support the potential of baricitinib as an additional treatment option for patients with moderate-to-severe AD, in whom treatment choices are otherwise limited. 

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).